Diabetic dyslipidemia

American Journal of Cardiology

Volumn 82, Issue 12 A, 1998, Pages 67U-73U

  Kreisberg, Robert A ^a  

^a Baptist Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER TOXICITY; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0032542240     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00848-0     Document Type: Conference Paper

References (33)

1. Bierman EL. Atherogenesis in diabetes. George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1992;12:647-656.
2. Raman M, Nesto RW. Heart disease in diabetes mellitus. Chronic complications in diabetes. Endocrinol Metab Clin North Am 1996;25:425-438.
3. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263: 2893-2898.
4. Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350(suppl I):20-23.
5. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh VL, Getz GS, Polonsky KS. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-944.
6. Cowie CC, Harris MI. Physical and metabolic characteristics of persons with diabetes. Diabetes in America. 2nd ed. National Institutes of Health. 1995:117-164.
7. Feingold KR, Grunfeld C, Pang M, Coerrler W, Krauss RM. LDL-C subclass phenotypes and triglyceride in non-insulin-dependent diabetes. Arterioscler Thromb Vasc Biol 1992;12:1496-1502.
8. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-889.
9. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329-1443.
10. Feingold KR, Grunfeld C, Pang M, Doerrier W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb Vasc Biol 1992;12:1496-1502.
11. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-199.
12. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Arch Intern Med 1990;150:1653-1657.
13. Nordestgaard BG, Nielson LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994;5:252-25T.
14. Koskinen P, Mänttäri M, Manninen V, HuHaneu JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-825.
15. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, and the Scandinavian Simvastatin Survival Study (4S) Group. Diabetes Care 1997;20:614-620.
16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnols JMO, Wun CC, David BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
17. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770.
18. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-169.
19. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1995;231:360-381.
20. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-422.
21. Vinik AI, Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 1993;16:37-44.
22. Lahdenperä S, Tilly-Kiesi M, Kuusi T. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584-592.
23. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 1989;38:364-372.
24. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16:5-13.
25. Henry P, Makowski S, Richard P, Beverelli F, Casanova S, Louali A, Boughalem K, Battaglia S, Guize L, Guermonprez J. Increased incidence of moderate stenosis among patients with diabetes: substrate for myocardial infarction. Am Heart J 1997;134:1037-1043.
26. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:536-539.
27. Harris MI. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care 1991;14:366-374.
28. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-268.
29. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1976;19(suppl 2):785-930.
30. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS, and the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM) Group. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med 1997;157:181-188.
31. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojimi Y, Furuyoshi N, Shichira M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-107.
32. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 1998;316:823-828.
33. Meyers DG. Relative survival benefit of risk factor modifications. Am J Cardiol 1996;77:298-299.